Skip to Content

Bio-Techne Corp TECH

Morningstar Rating
$80.60 +1.93 (2.45%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

TECH is trading at a 790% premium.
Price
$80.60
Fair Value
$23.00
Uncertainty
High
1-Star Price
$842.42
5-Star Price
$74.50
Economic Moat
Wrmhsb
Capital Allocation
Xslnfjps

Bulls Say, Bears Say

Bulls

The firm's reputation for excellent proteomic reagents and instruments allow it to generate high profit margins and strong cash flow.

Bears

Bio-Techne's long-term strategy relies on acquisitions, and the company may have difficulty finding suitable targets due to high valuations or scarcity. Additionally, it may fail to successfully integrate and scale up an acquired business.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TECH is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$78.67
Day Range
$78.7781.32
52-Week Range
$51.7985.95
Bid/Ask
$79.26 / $81.88
Market Cap
$12.70 Bil
Volume/Avg
969,063 / 1.1 Mil

Key Statistics

Price/Earnings (Normalized)
43.80
Price/Sales
11.25
Dividend Yield (Trailing)
0.40%
Dividend Yield (Forward)
0.40%
Total Yield
1.03%

Company Profile

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Core
Total Number of Employees
3,050

Competitors

Valuation

Metric
TECH
BIO
TMO
Price/Earnings (Normalized)
43.8026.6628.08
Price/Book Value
6.301.014.89
Price/Sales
11.253.555.53
Price/Cash Flow
40.8913.4927.23
Price/Earnings
TECH
BIO
TMO

Financial Strength

Metric
TECH
BIO
TMO
Quick Ratio
2.494.481.19
Current Ratio
4.086.571.70
Interest Coverage
14.52−9.704.83
Quick Ratio
TECH
BIO
TMO

Profitability

Metric
TECH
BIO
TMO
Return on Assets (Normalized)
10.95%2.49%8.69%
Return on Equity (Normalized)
14.98%3.50%18.71%
Return on Invested Capital (Normalized)
12.39%2.78%10.97%
Return on Assets
TECH
BIO
TMO
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
TdjydcmzzMcz$565.6 Bil
Vertex Pharmaceuticals Inc
VRTX
SfbswbsDxrzdg$127.8 Bil
Regeneron Pharmaceuticals Inc
REGN
HsfqykdKnkytyn$118.7 Bil
Moderna Inc
MRNA
FzhnsbmbJyvj$46.8 Bil
Alnylam Pharmaceuticals Inc
ALNY
NtkphprchWhlgwkp$29.7 Bil
argenx SE ADR
ARGX
FphckvcWdn$29.3 Bil
BioNTech SE ADR
BNTX
LfpkxfzXwqv$20.7 Bil
Biomarin Pharmaceutical Inc
BMRN
MljssvmjhBdtjb$16.1 Bil
United Therapeutics Corp
UTHR
JsfqwprhLvyy$15.0 Bil
Incyte Corp
INCY
SvykmjvzTxlpkjm$13.5 Bil

Sponsor Center